In May, another amyloid targeting drug for Alzheimer's disease – AC Immune and Roche's crenezumab – missed the mark in another clinical trial and looked destined for the scrap heap like so
The litany of failed trials of amyloid-targeting drugs for Alzheimer's disease has added another verse, as Roche concedes that its crenezumab candidate was unable to slow cognitive decline
The first patients are now being treated as part of a first-in-human trial of a vaccine, administered as a nasal spray, that aims to slow down the progression of Alzheimer's disease (AD).
Shares in AC Immune leaped today after the company said its tau-targeting Alzheimer's disease candidate semorinemab hit one of its objectives in a phase 2 trial, although it missed another.
Shares in Swiss biotech AC Immune have risen sharply after it said a vaccine in development for Alzheimer’s disease (AD) hit the mark in a phase 1/2 trial.
Shares in AC Immune have collapsed after partner Genentech revealed its tau-targeting Alzheimer’s drug semorinemab had flunked a phase 2 trial in Alzheimer’s disease (AD).
Japan’s Taisho Pharmaceutical looks like it could be heading into private ownership, thanks to a management buyout offer (MBO) that could value the company at almost $5 bi
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio